42 results
CORRESP
VERV
Verve Therapeutics Inc
4 Jun 21
Correspondence with SEC
12:00am
of each grant, considering the Company’s most recently available independent third-party valuation of its common stock and the Board’s assessment …
The Company performed a retrospective fair value assessment and concluded that the fair value of the common stock underlying stock options that the Company
8-K
VERV
Verve Therapeutics Inc
2 Apr 24
Other Events
7:13am
Heart-1 trial, including the Company’s assessment of the laboratory abnormalities observed in the trial and the Company’s interactions with regulatory
10-K
2021 FY
VERV
Verve Therapeutics Inc
14 Mar 22
Annual report
7:04am
and reliable assessment of clinical benefit, particularly in an area of unmet medical need.
In some cases, the FDA may approve a BLA for a product … submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant
8-K
EX-99.1
VERV
Verve Therapeutics Inc
8 May 24
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
7:15am
for the company’s Heart-1 clinical trial, including the company’s assessment of the laboratory abnormalities observed in the trial and the company’s
S-1
jywecg spg2wk
28 May 21
IPO registration
4:04pm
424B4
691ktkjph
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
tte7ge0lhg1po dxz
14 Jun 21
IPO registration (amended)
6:15am
DRS
q4r22qy7fa3ob
16 Apr 21
Draft registration statement
12:00am
DRS
EX-10.15
25kku
16 Apr 21
Draft registration statement
12:00am
S-1
EX-10.14
4y162
28 May 21
IPO registration
4:04pm